Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00621244 · OUTCOME

Maximum Plasma Concentration of Panobinostat After Multiple Doses in Arm 1 on Day 15

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies · Source last updated 2021-01-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Standard Deviation
Time frame
Day 15

What was measured

From day 15 by dose with schedule: MWF every week

Analysis population: Pharmacokinetic set

Groups in this outcome

20 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

30 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

40 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

60 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

80 mg

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
20 mg8
30 mg12
40 mg22
60 mg17
80 mg4

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
20 mg33.616.33Not reportedNot reportedNot reported
30 mg38.423.58Not reportedNot reportedNot reported
40 mg41.636.54Not reportedNot reportedNot reported
60 mg51.828.78Not reportedNot reportedNot reported
80 mg69.626.78Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.33
        value
        33.6
      2. group Id
        OG001
        spread
        23.58
        value
        38.4
      3. group Id
        OG002
        spread
        36.54
        value
        41.6
      4. group Id
        OG003
        spread
        28.78
        value
        51.8
      5. group Id
        OG004
        spread
        26.78
        value
        69.6
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    2. group Id
      OG001
      value
      12
    3. group Id
      OG002
      value
      22
    4. group Id
      OG003
      value
      17
    5. group Id
      OG004
      value
      4
    units
    Participants
description
From day 15 by dose with schedule: MWF every week
dispersion Type
Standard Deviation
groups
  1. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG000
    title
    20 mg
  2. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG001
    title
    30 mg
  3. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG002
    title
    40 mg
  4. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG003
    title
    60 mg
  5. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG004
    title
    80 mg
param Type
MEAN
population Description
Pharmacokinetic set
reporting Status
POSTED
time Frame
Day 15
title
Maximum Plasma Concentration of Panobinostat After Multiple Doses in Arm 1 on Day 15
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice